Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Saved in:
| Title: | Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. |
|---|---|
| Authors: | Lewis, David J (AUTHOR), Jerkeman, Mats (AUTHOR), Sorrell, Lexy (AUTHOR), Wright, David (AUTHOR), Glimelius, Ingrid (AUTHOR), Poulsen, Christian B (AUTHOR), Pasanen, Annika (AUTHOR), Rawstron, Andrew (AUTHOR), Wader, Karin F (AUTHOR), Morley, Nick (AUTHOR), Burton, Catherine (AUTHOR), Davies, Andrew J (AUTHOR), Lagerlöf, Ingemar (AUTHOR), Dalal, Surita (AUTHOR), De Tute, Ruth (AUTHOR), McNamara, Chris (AUTHOR), Crosbie, Nicola (AUTHOR), Toldbod, Helle Erbs (AUTHOR), Sanders, Jeanette (AUTHOR), Allgar, Victoria (AUTHOR) |
| Source: | Lancet. Oct2025, Vol. 406 Issue 10514, p1953-1968. 16p. |
| Subjects: | Mantle cell lymphoma, Rituximab, Bruton tyrosine kinase, Medical quality control, Progression-free survival, Clinical trials, Immunoassay, Randomized controlled trials |
| Abstract: | Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib–rituximab) with standard immunochemotherapy (R-CHOP [rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine–rituximab) in patients 60 years and older with untreated mantle-cell lymphoma. This randomised, open-label, phase 2/3 superiority trial was performed at 66 sites in the UK, Sweden, Norway, Finland, and Denmark. Patients 60 years and older with untreated mantle-cell lymphoma (Ann–Arbor stage II–IV disease, an Eastern Cooperative Oncology Group performance-status score of 0–2) were randomly assigned to receive either rituximab plus immunochemotherapy or ibrutinib–rituximab in a 1:1 ratio, stratified by investigator choice of immunochemotherapy. Patients randomly allocated to the ibrutinib–rituximab (intervention) group received 560 mg oral ibrutinib daily in combination with six to eight cycles of 375 mg/m2 intravenous rituximab on day 1 of each cycle in the matched schedule of the pre-randomisation choice of immunochemotherapy (every 21 days for R-CHOP or every 28 days for rituximab–bendamustine). R-CHOP comprised 750 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin, and 1·4 mg/m2 vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1–5 of each cycle. Rituximab–bendamustine comprised 90 mg/m2 of bendamustine on days 1 and 2 of each cycle, in combination with 375 mg/m2 rituximab on day 1 of each cycle. All responding patients in both groups at the end of induction received maintenance rituximab administered every 8 weeks for 2 years, and patients allocated to the intervention group continued ibrutinib until disease progression or unacceptable toxicity. The primary outcome was investigator-assessed progression-free survival, stratified by immunochemotherapy choice and analysed in the intention-to-treat population. The trial was registered with EudraCT (2015–000832–13) and is closed for recruitment. Between Feb 15, 2016, and June 30, 2021, 397 patients were randomly allocated to immunochemotherapy (control) or ibrutinib–rituximab (intervention). Of the 397, 107 (27%) were pre-allocated to the immunochemotherapy choice of R-CHOP and 290 (73%) were pre-allocated to rituximab–bendamustine. In total, 198 were allocated to the control group (53 to R-CHOP and 145 to bendamustine–rituximab) and 199 were allocated to intervention. The median age was 74 years (IQR 70–77) for the intervention group and 74 years (70–78) in the control group. 296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected. At a median follow-up of 47·9 months, the median progression-free survival of ibrutinib–rituximab was superior to immunochemotherapy, with an adjusted hazard ratio (HR) of 0·69 (95% CI 0·52–0·90); p=0·0034. For those with pre-randomisation choice R-CHOP, the HR was 0·37 (0·22–0·62), and with bendamustine–rituximab, the HR was 0·91 (0·66–1·25). Across induction and maintenance, 67% of patients assigned to ibrutinib–rituximab and 70% of patients receiving immunotherapy reported grade 3 or above adverse events. To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immunochemotherapy. This study suggests that ibrutinib–rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma. Cancer Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals. [ABSTRACT FROM AUTHOR] |
| Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 188829936 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Lewis%2C+David+J%22">Lewis, David J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jerkeman%2C+Mats%22">Jerkeman, Mats</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sorrell%2C+Lexy%22">Sorrell, Lexy</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wright%2C+David%22">Wright, David</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Glimelius%2C+Ingrid%22">Glimelius, Ingrid</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Poulsen%2C+Christian+B%22">Poulsen, Christian B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pasanen%2C+Annika%22">Pasanen, Annika</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rawstron%2C+Andrew%22">Rawstron, Andrew</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wader%2C+Karin+F%22">Wader, Karin F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morley%2C+Nick%22">Morley, Nick</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burton%2C+Catherine%22">Burton, Catherine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Davies%2C+Andrew+J%22">Davies, Andrew J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lagerlöf%2C+Ingemar%22">Lagerlöf, Ingemar</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dalal%2C+Surita%22">Dalal, Surita</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Tute%2C+Ruth%22">De Tute, Ruth</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22McNamara%2C+Chris%22">McNamara, Chris</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Crosbie%2C+Nicola%22">Crosbie, Nicola</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toldbod%2C+Helle+Erbs%22">Toldbod, Helle Erbs</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sanders%2C+Jeanette%22">Sanders, Jeanette</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Allgar%2C+Victoria%22">Allgar, Victoria</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. Oct2025, Vol. 406 Issue 10514, p1953-1968. 16p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Mantle+cell+lymphoma%22">Mantle cell lymphoma</searchLink><br /><searchLink fieldCode="DE" term="%22Rituximab%22">Rituximab</searchLink><br /><searchLink fieldCode="DE" term="%22Bruton+tyrosine+kinase%22">Bruton tyrosine kinase</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+quality+control%22">Medical quality control</searchLink><br /><searchLink fieldCode="DE" term="%22Progression-free+survival%22">Progression-free survival</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Immunoassay%22">Immunoassay</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib–rituximab) with standard immunochemotherapy (R-CHOP [rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine–rituximab) in patients 60 years and older with untreated mantle-cell lymphoma. This randomised, open-label, phase 2/3 superiority trial was performed at 66 sites in the UK, Sweden, Norway, Finland, and Denmark. Patients 60 years and older with untreated mantle-cell lymphoma (Ann–Arbor stage II–IV disease, an Eastern Cooperative Oncology Group performance-status score of 0–2) were randomly assigned to receive either rituximab plus immunochemotherapy or ibrutinib–rituximab in a 1:1 ratio, stratified by investigator choice of immunochemotherapy. Patients randomly allocated to the ibrutinib–rituximab (intervention) group received 560 mg oral ibrutinib daily in combination with six to eight cycles of 375 mg/m2 intravenous rituximab on day 1 of each cycle in the matched schedule of the pre-randomisation choice of immunochemotherapy (every 21 days for R-CHOP or every 28 days for rituximab–bendamustine). R-CHOP comprised 750 mg/m2 of cyclophosphamide, 50 mg/m2 of doxorubicin, and 1·4 mg/m2 vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1–5 of each cycle. Rituximab–bendamustine comprised 90 mg/m2 of bendamustine on days 1 and 2 of each cycle, in combination with 375 mg/m2 rituximab on day 1 of each cycle. All responding patients in both groups at the end of induction received maintenance rituximab administered every 8 weeks for 2 years, and patients allocated to the intervention group continued ibrutinib until disease progression or unacceptable toxicity. The primary outcome was investigator-assessed progression-free survival, stratified by immunochemotherapy choice and analysed in the intention-to-treat population. The trial was registered with EudraCT (2015–000832–13) and is closed for recruitment. Between Feb 15, 2016, and June 30, 2021, 397 patients were randomly allocated to immunochemotherapy (control) or ibrutinib–rituximab (intervention). Of the 397, 107 (27%) were pre-allocated to the immunochemotherapy choice of R-CHOP and 290 (73%) were pre-allocated to rituximab–bendamustine. In total, 198 were allocated to the control group (53 to R-CHOP and 145 to bendamustine–rituximab) and 199 were allocated to intervention. The median age was 74 years (IQR 70–77) for the intervention group and 74 years (70–78) in the control group. 296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected. At a median follow-up of 47·9 months, the median progression-free survival of ibrutinib–rituximab was superior to immunochemotherapy, with an adjusted hazard ratio (HR) of 0·69 (95% CI 0·52–0·90); p=0·0034. For those with pre-randomisation choice R-CHOP, the HR was 0·37 (0·22–0·62), and with bendamustine–rituximab, the HR was 0·91 (0·66–1·25). Across induction and maintenance, 67% of patients assigned to ibrutinib–rituximab and 70% of patients receiving immunotherapy reported grade 3 or above adverse events. To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immunochemotherapy. This study suggests that ibrutinib–rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma. Cancer Research UK (C7627/A17938) and Johnson and Johnson Pharmaceuticals. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=188829936 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0140-6736(25)01432-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 16 StartPage: 1953 Subjects: – SubjectFull: Mantle cell lymphoma Type: general – SubjectFull: Rituximab Type: general – SubjectFull: Bruton tyrosine kinase Type: general – SubjectFull: Medical quality control Type: general – SubjectFull: Progression-free survival Type: general – SubjectFull: Clinical trials Type: general – SubjectFull: Immunoassay Type: general – SubjectFull: Randomized controlled trials Type: general Titles: – TitleFull: Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lewis, David J – PersonEntity: Name: NameFull: Jerkeman, Mats – PersonEntity: Name: NameFull: Sorrell, Lexy – PersonEntity: Name: NameFull: Wright, David – PersonEntity: Name: NameFull: Glimelius, Ingrid – PersonEntity: Name: NameFull: Poulsen, Christian B – PersonEntity: Name: NameFull: Pasanen, Annika – PersonEntity: Name: NameFull: Rawstron, Andrew – PersonEntity: Name: NameFull: Wader, Karin F – PersonEntity: Name: NameFull: Morley, Nick – PersonEntity: Name: NameFull: Burton, Catherine – PersonEntity: Name: NameFull: Davies, Andrew J – PersonEntity: Name: NameFull: Lagerlöf, Ingemar – PersonEntity: Name: NameFull: Dalal, Surita – PersonEntity: Name: NameFull: De Tute, Ruth – PersonEntity: Name: NameFull: McNamara, Chris – PersonEntity: Name: NameFull: Crosbie, Nicola – PersonEntity: Name: NameFull: Toldbod, Helle Erbs – PersonEntity: Name: NameFull: Sanders, Jeanette – PersonEntity: Name: NameFull: Allgar, Victoria IsPartOfRelationships: – BibEntity: Dates: – D: 25 M: 10 Text: Oct2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 01406736 Numbering: – Type: volume Value: 406 – Type: issue Value: 10514 Titles: – TitleFull: Lancet Type: main |
| ResultId | 1 |
